CD47 and hepatocellular carcinoma: The knockdown or blocking of CD47 in sorafenib-resistant HCC cells consistently demonstrated an increased sensitization to sorafenib by these cells, suggesting that CD47 signaling might be involved in the sensitization to this drug.